Metronomics Global Health Initiative

Eddy PASQUIER

2011-06-03T08:45:58Z

Dr. Eddy Pasquier completed his PhD in Oncology at the University of Aix-Marseille, France in 2006. Shortly after, he joined the Children's Cancer Institute Australia (CCIA), first as a Post-Doctoral Research Officer and then as a Cancer Institute New South Wales Research Fellow. Currently, he is a Senior Research Officer and leads a small research team within the Tumour Biology and Targeting Program of CCIA. He is also a Lecturer (Conjoint) in the School for Women's and Children's Health at the Faculty of Medicine, University of New South Wales (Sydney, Australia). His awards include the Young Tall Poppy Science Award 2011 from the Australian Institute of Policy & Science, the Dean's Rising Star Award 2010 from the Faculty of Medicine, University of New South Wales, and the Children's Cancer Institute Australia Award 2008 for outstanding achievements in research and community engagement.

Over the past 10 years, Dr Pasquier has made significant contributions to the fields of tumour angiogenesis and innovative cancer therapies. His work on metronomic chemotherapy in particular contributed to elucidate some of the underlying molecular and cellular mechanisms of action of this multi-faceted therapy. Through his long-standing collaboration with Metronomics Global Health Initiative co-founder, Dr Nicolas Andre, Dr Pasquier also helped in the development of more effective metronomic protocols to be used in childhood cancer patients living in both high-income and low- to middle-income countries.

Drs Andre and Pasquier share the same vision that a different approach to cancer treatment is not only possible but mandatory. Their research effort is based on this common philosophy and aims at developing constraint-adapted, effective, cheap and non-toxic cancer therapies that can be used to treat childhood cancer patients wherever they live.

Selected publications about metronomics:

- André N, Abed S, Orbach D, Armari Alla C, Padovani L, Pasquier E et al. Pilot study of a pediatric metronomic 4-drug regimen.Oncotarget. 2012

- Pasquier E et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget 2011

- Pasquier E et al. Moving forward with metronomic treatments: meeting report of the 2nd international workshop on metronomic and anti-angiogenic chemotherapy in paediatric oncology. Translational Oncology 2011

- Fousseyni T, Diawara M, Pasquier E, André N. Children treated with metronomic chemotherapy in a low-income country: Metro-Mali-01. Journal of Pediatric Hematology Oncology 2011

- André N, Pasquier E, Gentet JC, Kamen B. Looking at the seemingly paradoxical effect of vinblastine in anaplastic large cell lymphoma from a “metronomic” point of view. Journal of Clinical Oncology 2011

-Pasquier E, Kavallaris M, André N. Metronomic Chemotherapy : New rationale for new directions. Nature Reviews Clinical Oncology 2010

- André N, Pasquier E. For cancer seek and destroy better than live and let live? Nature 2009

- André N, Pasquier E. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nature Reviews Clinical Oncology 2008

Other significant publications:

- Kan CY, Wen VW, Pasquier E et al. Endothelial cell dysfunction and cytoskeletal changes associated with repression of p16INK4a during immortalization. Oncogene 2012

- Shum MSY, Pasquier E et al. γ-actin regulates cell migration and modulates the ROCK signaling pathway. FASEB Journal 2011

- Pasquier E et al. ENMD-1198, a new analog of 2-methoxyestradiol, displays both anti-angiogenic and vascular-disrupting properties. Molecular Cancer Therapeutics 2010

- Pasquier E, Dias S. Endothelial progenitor cells: hope beyond controversy? Current Cancer Drug Targets 2010

- Pasquier E et al. Microtubule-targeting agents in angiogenesis: where do we stand? Drug Resistance Updates 2006

– Pasquier E et al. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Research 2005
Pasquier E et al. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signalling pathway. Molecular Cancer Therapeutics 2004

Marc Le Menestrel

2011-06-03T08:39:54Z

Marc Le Menestrel has been researching and teaching new forms of ethical business at University Pompeu Fabra (Spain) and INSEAD (France & Singapore) in the last ten years. An adept of crossing borders and of daring to live our dreams, he will look for the most innovative business models to promote the world our children want to live in.

Nicolas ANDRE

2011-06-03T08:30:49Z

Pr. Nicolas André is Professor in Pediatric Oncology in the Department of Hematology & Pediatric Oncology in the “Hôpital pour Enfants de La Timone”, AP-HM and head of the SMARTC CRCM- (Centre de Recherche en Cancérologie de Marseille), AMU, France.

He gained his medical degree in 2002 and a doctoral degree in 2003. He is the former president of the “Société Francophone de Recherche en Pédiatrie”. Currently, his research interests and topics include paediatric brain tumors, pediatric rare tumors and pharmacology (new anticancer agents, metronomic chemotherapy, microtubule-targeting agents).
His has developed over the years an international expertise in metronomic chemotherapy.

The use of metronomic chemotherapy in "his" own patients has convinced him that this tool could be valuable for children in developing countries. He initiated with Dr Fousseiny Traore a pilot study in Bamako (Mali) that further convinced him of the unveiled potential of metronomic chemotherapy.

He then imaginated Metronomics-Global-Health–Initiative as the structure that could promote the development of metronomics with the highest standards and pave the way for new global strategies to fight cancer in developing countries.

He will be the leader of Metronomics-Global-Health–Initiative connecting & coordinating a community of institutions and people who will embark in this forward-looking project as inventors, ambassadors, sponsors and supporters.

He is the author of over 100 peer reviewed publications and book chapters and has given lectures on metronomics worldwide.

Selected publications about metronomics:

– Ciccolini J, Barbolosi D, Meille C, Lombard A, Serdjebi C, Giacometti S, Padovani L, Pasquier E, André N. Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic Chemotherapy.
Cancer Res 2017
– André N, Tsai K, Carré M, Pasquier EMetronomic Chemotherapy: Direct Targeting of Cancer Cells after all? Trends Cancer 2017
– André N, Banavali S, Pasquier E.Paediatrics: Metronomics - fulfilling unmet needs beyond level A evidence.
Nature Rev Clin Oncol 2016
– André N, M Carré, Pasquier E. Metronomics : toward personalized chemotherapy. Nature Rev Clin Oncol 2014
– André N, Pasquier E . For cancer seek and destroy better than live and let live? Nature 2009
– André N, Banavali, S Snihur J, Pasquier E . Has the time come for metronomics in low-income and middle-income countries? Lancet Oncology 2013
– Pasquier E, Kavallaris M, André N. Metronomic Chemotherapy : New rationale for new directions. Nature Rev Clin Oncol 2010
– André N, Pasquier E, Kamen B. Looking at the seemingly paradoxical effect of vinblastine in anaplastic large cell lymphoma from a “metronomic” point of view J Clin Oncol 2011
– André N et al.Pilot study of a pediatric metronomic 4-drug regimen. Oncotarget. 2012
– Pasquier E, Ciccolini J, Carré M, Giacometti S, Fanciullino R, Pouchy C, Montero MP, Serdjebi C, Kavallaris M, André N. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment.Oncotarget 2011
– Traore F, Nanoudiara M, Pasquier E, André N. Metronomic chemotherapy in a low-income country: METRO-MALI-01 J Pediatr Hematol Oncol. 2011
– André N, Fousseyni T, Banavali S, Pasquier E. Metronomic chemotherapy : a way forward for low income countries? Oncopedia 2012
– André N, Pasquier E, Kamen E. Can Targeted Therapy be Successful without Metronomic Scheduling ? Currents Topics in Medicinal Chemistry 2012

Other publications

– André N, Guercio B, Pasquier E. Investment in cancer studies in countries of low and middle income. The Lancet. 2013
– André N. Hippocrates of Cos and Apoptosis. The Lancet 2003
– André N. Involving children in paediatric oncology decision-making. Lancet Oncol 2004.
– Mateo V, Ménager V, de Saint-Basile G, Stolzenberg MC, Roquelaure B, André N, et al. Perforin-dependent apoptosis compensates Fas-deficiency in Activation-Induced Cell-Death of human T lymphocytes. Blood 2007
– Cicollini J, Dahan L, André N et al. CDA residual activity in serum is a predicitive marker of severe early toxicities after gemcitabine-based chemotherapies. J Clin Oncol 2010
– Ciccolini J, Mercier C, Dahan L, André N. pharmacogenetic of gemcitabine : time for a change ! Nature Rev Clin Oncol 2011
– Padovani L, André N, Constine L, Murraxiole X. Neurocognitive toxcity of radiotherapy in children with cancer. Nature Reviews Neurology 2012